Business

Lucid Diagnostics to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Thursday, April 10, 2025 at 11:00 AM EDT.

articleLucid Diagnostics Inc.April 3, 20253/company/lucid-diagnostics-inc/news/lucid-diagnostics-participate-fireside-chat-130000263
Lucid Diagnostics to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

About this update from Lucid Diagnostics Inc.

[{"type":"text","content":"NEW YORK, April 3, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Thursday, April 10, 2025 at 11:00 AM EDT.","length":481,"tagName":"p"},{"type":"image","alt":"Lucid Diagnostics Inc., markets the first and only commercial tools for widespread early detection of esophageal precancer and cancer – the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device. (PRNewsfoto/Lucid Diagnostics)","displaySize":"","headline":null,"caption":"Lucid Diagnostics Inc., markets the first and only commercial tools for widespread early detection of esophageal precancer and cancer – the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device. (PRNewsfoto/Lucid Diagnostics)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":107,"url":"https://media.zenfs.com/en/prnewswire.com/9ee0d0ae0eda5368bcc0b17e848d707c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/EIajbOKjadbArgiAenSE8w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE4OTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/9ee0d0ae0eda5368bcc0b17e848d707c","width":400,"height":107}},"href":"https://mma.prnewswire.com/media/2003008/Lucid_TM_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The fireside chat will be webcast live and can be accessed by visiting the Investor Relations Section of the Lucid Diagnostics website or by clicking here.  A replay of the webcast will be available on the website for 30 days following the conclusion of the live broadcast. Company management will meet with investors in one-on-one meetings during the conference.","length":368,"tagName":"p","attribs":{}},{"type":"text","content":"About Lucid DiagnosticsLucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk...

More updates from Lucid Diagnostics Inc.

Lucid DiagnosticsLucid Diagnostics Inc.fireside chatPAVmed Inc.LucidForward-Looking Statements